NZ775003B2 - Fused ring compounds - Google Patents
Fused ring compounds Download PDFInfo
- Publication number
- NZ775003B2 NZ775003B2 NZ775003A NZ77500319A NZ775003B2 NZ 775003 B2 NZ775003 B2 NZ 775003B2 NZ 775003 A NZ775003 A NZ 775003A NZ 77500319 A NZ77500319 A NZ 77500319A NZ 775003 B2 NZ775003 B2 NZ 775003B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- halo
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 19
- 150000003839 salts Chemical class 0.000 claims 15
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 1
- 125000005228 aryl sulfonate group Chemical group 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- -1 p- toluenesulfonyl Chemical group 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000016914 ras Proteins Human genes 0.000 abstract 1
- 108010014186 ras Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
This invention pertains to fused ring compounds of Formula (II), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
Claims (16)
1. A compound of Formula (II): or a pharmaceutically acceptable salt thereof; wherein, R is NH ; R is H; R is H or C alkyl; 4 1-6 R is CF ; R is selected from the group consisting of H, cyano, and halo; R and R are each independently selected from the group consisting of H, C alkyl, 8 9 1-6 C haloalkyl, C hydroxyalkyl, cyano, and halo; wherein C alkyl is optionally substituted 1-6 1-6 1-6 with one substituent selected from the group consisting of: methanesulfonyl (mesyl), p- toluenesulfonyl (tosyl), an alkyl or aryl sulfonate leaving group, C alkanoylamino, C 1-6 1-6 alkoxy, C alkylamino, C alkylsulfonylamino, C dialkylamino, and C haloalkoxy; 1-6 1-6 6-12 1-6 X is piperazinyl optionally substituted with 1 to 4 substituents, wherein each substituent is independently selected from the group consisting of cyano, C alkyl, C cyanoalkyl, and 1-6 1-6 C haloalkyl; Y is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , U is C(R ), wherein R is H; 6a 6a V is C(R ), wherein R is H or halo; 6b 6b W is C(R ), wherein R is H or halo ; 6c 6c n is 0.
2. The compound or pharmaceutically acceptable salt thereof of claim 1, wherein X , , , , , , , , , , , , , or .
3. The compound of claim 1 or 2, or pharmaceutically acceptable salt thereof, wherein Y is or .
4. The compound of claim 1, having Formula (IV): or a pharmaceutically acceptable salt thereof; wherein, R is , , , , or ; X is , , , , , , , , , , , , , or Y is or ; U is C(R ), wherein R is H; 6a 6a V is C(R ), wherein R is H or halo; 6b 6b W is C(R ), wherein R is H or halo; 6c 6c n is 0; and R is selected from the group consisting of: , , , , , , , and , .
5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is , or .
6. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R is .
7. The compound of any one of claims 4-6, or a pharmaceutically acceptable salt thereof, wherein R is , , or .
8. The compound of any one of claims 4-7, or a pharmaceutically acceptable salt thereof, wherein R is
9. The compound of any one of claims 4-6, or a pharmaceutically acceptable salt thereof, wherein R11 is , , or .
10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R is halo.
11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen.
12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R is halo.
13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein X is , , or .
14. The compound of claim 1 having a Formula : (Ia); (Ib); (Ic); (Ih); or (Il), or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 or 4 having formula: (IVa); (IVb); (IVc); (IVd); or (IVg), or a pharmaceutcially acceptable salt thereof.
16. The compound of claim 1, having formula: °Y^ °Y^ °Y^ Cl Cl Cl N^O N^O N^O h2n. .n h2n. .n h2n^ ^n. 5^ V' V' / / / 'CF3 'CF3 'CF3 , , , O^Y^^F QY^^f Cl Cl Cl N^O N^O N^O H2N. .N, H2Nv.N H2Nv-N s"'.. >. S"'.. F F N—' F N^y / / / CF3 cf3 cf3 , , , . ^Nk ^ ,N-. f^fci fJ1 Cl N^O F s"'.. NH2 nh2 nh2 , , , QY'^k F^VN> F FCI nh2 nh2 nh2 , , , fJ^ci F. Cl N r n H2N. .N Or* L> nh2 nh2 , , , / <-J ¦Z Z— C _j~i. o z—i' z /--- \ •z z—(/ z z z^/ LK •z z z Z—<' z o o N—/ \\ /“V \\ /r^ o jr% o z \ \ LL \ \ LL- •z Z—v / \ K K z z-(/ z ^ W5 ¦z z-!/ Z Z—v z \\ ^“V \\ //^v LL? LjCO o zr^ X X X , , , , , HzN^N. CF3 / Cl r n H2N. .N h2n_n •s: / ¦cf3 / h2n^n HjN^N n^Xqy":. r>0Et ¦CF3 ¦CF3 Cl Cl H2N N. h2n_n y"'-. ¦cf3 ‘CF3 h2n^n. CX0X h2n M N*...O oCfF O N N~V ¦CF3 / CF3 , , , Cl Cl h2n
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018114788 | 2018-11-09 | ||
| PCT/US2019/060578 WO2020097537A2 (en) | 2018-11-09 | 2019-11-08 | Fused ring compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ775003A NZ775003A (en) | 2024-07-05 |
| NZ775003B2 true NZ775003B2 (en) | 2024-10-08 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2820020T3 (en) | PYRAZOLOTRIAZINE DERIVATIVES AS SELECTIVE CYCLIN DEPENDENT KINASE INHIBITORS | |
| Ghorab et al. | Synthesis and pharmacophore modeling of novel quinazolines bearing a biologically active sulfonamide moiety | |
| HU221507B (en) | Pyrazolo-pyrimidine derivatives, pharmaceutical compositions containing them as active agents process for the preparation thereof | |
| MX2010001677A (en) | 4-(9-(3, 3-difluorocyclopentyl) -5, 7, 7-trimethyl-6-oxo-6, 7, 8, 9-tetrahydro-5h-pyrimido [4, 5-b[1, 4] diazepin-2-ylamino)-3-met hoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative di | |
| WO2003024967A3 (en) | Indolizines as kinase protein inhibitors | |
| EA200401612A1 (en) | ANTIALLERGICAL MEANS | |
| JP2007519694A5 (en) | ||
| EA200400452A1 (en) | DERIVATIVES OF 3-SUBSTITUTED 4-PYRIMIDONES | |
| JP2017511357A5 (en) | ||
| RU2010121763A (en) | Pyridazinone derivatives and P2X7 receptor inhibitors | |
| AU2003301226A2 (en) | Acyclic Pyrazole Compounds | |
| AR043673A1 (en) | NON-NUCLEOSID INHIBITING HETEROCICLICAL COMPOUNDS OF THE REVERSE TRANSCRIPT I, PREPARATION OF THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF AIDS | |
| EA200400453A1 (en) | DERIVATIVES OF 3-SUBSTITUTED 4-PYRIMIDONES | |
| AR069919A1 (en) | BIS- (SULFONYLAMINE) DERIVATIVES USEFUL FOR PAIN TREATMENT | |
| EA201390022A8 (en) | CONDENSED HETEROCYCLIC COMPOUNDS AS PHOSPHODYSTERASE INHIBITORS (PDE) Inhibitors | |
| IL283368B1 (en) | An imidazo[2,1-b]pyridazin-7-ylurea compound and a drug containing the compound | |
| MX2015002270A (en) | Novel 4,6-disubstituted aminopyrimidine derivatives. | |
| EA201990902A1 (en) | BRUTON TYROSINKINASE INHIBITORS | |
| JP2016501185A5 (en) | ||
| JP2016540803A5 (en) | ||
| EA200971063A1 (en) | ARYLAMIDPYRIMIDONE COMPOUNDS | |
| PH12020550761A1 (en) | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF | |
| EA200801134A1 (en) | REPLACED BICYCLIC PYRIMIDON DERIVATIVES | |
| EA200971062A1 (en) | DERIVATIVES OF ARYLAMIDPYRIMIDONE | |
| RU2006138606A (en) | KINASE INHIBITORS |